Supplementary Information Tables: 2015–16 Report on Plans and Priorities

Horizontal Initiatives

Federal Initiative to Address HIV/AIDS in Canada (FI)

Canadian HIV Vaccine Initiative (CHVI)

Federal Initiative to Address HIV/AIDS in Canada (FI)

General Information

Name of horizontal initiative: Federal Initiative to Address HIV/AIDS in Canada (FI)

Name of lead department(s): Public Health Agency of Canada (Agency)

Federal partner organization(s): Health Canada (HC), Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC)

Non-federal and non-governmental partner(s): Not applicable (N/A)

Start date of the horizontal initiative: January 13, 2005

End date of the horizontal initiative: Ongoing

Total federal funding allocated (start to end date): Ongoing

Funding contributed by non-federal and non-governmental partners: N/A

Description of the horizontal initiative:

Objective(s):

  • To increase knowledge of the epidemic, through research on the factors that contribute to it and on better methods to respond effectively, including a sentinel surveillance system to track the epidemic;
  • To increase the availability of evidence-based HIV interventions that are centred on the needs of at-risk populations and people living with HIV/AIDS; and
  • To increase the awareness of the need for HIV testing, access to prevention, treatment and care and supporting social environments for people living with or at risk of acquiring HIV.

Why this HI is Necessary:

  • The FI Evaluation indicated that HIV/AIDS remains a persistent public health issue for Canada that disproportionately affects vulnerable populations. While the rate of infection of HIV/AIDS has stabilized, new cases continue to be diagnosed. As such, prevention efforts are still needed as well as greater emphasis on increasing access to testing, diagnosis and treatment; and
  • A coordinated, coherent, and integrated federal response is needed to identify and scale up the most effective responses to HIV and AIDS in Canada, and to contribute to global efforts to address HIV.

Intervention Method(s):

Government of Canada partners are responsible for:

  • Public health laboratory science and services;
  • Surveillance;
  • The development of public health practice guidance;
  • Knowledge synthesis;
  • Program policy development;
  • Public awareness;
  • Capacity building;
  • Education and prevention activities for First Nations living on reserve, Inuit living south of the 60th parallel and federal inmates;
  • Facilitating the creation of new knowledge through research funding;
  • Delivering public health and health services to federal inmates; and
  • Supporting the community-based response through grants and contributions funding.

Partners develop multi-sector partnerships and collaborative efforts to address factors which can increase the transmission and acquisition of HIV. This includes sexually transmitted infections (STIs) and co-infection issues with other infectious diseases (e.g., Hepatitis C and tuberculosis). People living with and vulnerable to HIV/AIDS are active partners in FI policies and programs.

Shared outcome(s):Footnote 7

First level outcomes:

  • Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease;
  • Increased individual and organizational capacity;
  • Increased Canadian engagement and leadership in the global context; and
  • Enhanced engagement and collaboration on approaches to address HIV and AIDS.

Second level outcomes:

  • Reduced stigma, discrimination, and other barriers;
  • Improved access to more effective prevention, care, treatment and support;
  • Internationally informed federal response; and
  • Increased coherence of the federal response.

Ultimate outcomes:

  • Prevent the acquisition and transmission of new infections;
  • Improved quality of life for those at risk and living with HIV and AIDS;
  • Contribute to the global effort to reduce the spread of HIV and AIDS and mitigate its impact; and
  • Contribute to the strategic outcomes of partner departments.

Governance structures:

  • The Responsibility Centre Committee (RCC) is the governance body for the FI. It is comprised of directors or equivalent from the eight responsibility centres which receive funding through the FI. Led by the Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and enables evaluation, performance measurement, and reporting requirements to be met;
  • The Agency is the federal lead for issues related to HIV and AIDS in Canada. It is responsible for laboratory science, surveillance, program development, knowledge exchange, public awareness, guidance for health professionals, global collaboration and coordination;
  • HC supports HIV and AIDS prevention, education and awareness, community capacity building, as well as facilitating access to quality HIV/AIDS diagnosis, care, treatment, and support to on-reserve First Nations and Inuit communities south of the 60th parallel;
  • As the GoC's agency for health research, the CIHR supports the creation of new scientific knowledge and enables its translation into improved health, more effective health services and products, and a strengthened Canadian health care system; and
  • CSC, an agency of the Public Safety Portfolio, provides health services (including services related to the prevention, diagnosis, care and treatment of HIV and AIDS) to offenders sentenced to two years or more.

Planning highlights:Footnote 8

  • Continue to develop integrated approaches to HIV and related communicable diseases to address barriers to prevention, diagnosis, care, treatment, and support;
  • Programs will facilitate the creation, advancement and exchange of knowledge and its application into action; and
  • Programs will enhance robust horizontal governance, planning, monitoring and reporting on results.

Results to be achieved by non-federal and non-governmental partners: N/A

Contact information
Marsha Hay Snyder
Director, Programs and Partnerships Division
(613) 957-1345
100 Eglantine Drive
Ottawa, ON K1A 0K9
marsha.hay-snyder@phac-aspc.gc.ca

Planning Information
Federal organizations Link to departmental Program Alignment Architectures Contributing programs and activities Total allocation (from start to end date) 2015–16 Planned spending 2015–16 Expected results
The Agency Public Health Infrastructure Public Health Laboratory Systems Ongoing 5,056,959 ER 1.1
ER 1.2
ER 1.3
Health Promotion and Disease Prevention Infectious and Communicable Diseases Ongoing 2,434,753 ER 1.1
ER 1.2
Healthy Communities Ongoing 32,611,714 ER 1.1
ER 1.2
ER 1.3
HC First Nations and Inuit Primary Health Care Sexually Transmitted and Blood Borne Infections --HIV/AIDS Ongoing 4,515,000 ER 2.1
CIHR Health and Health Services Advances Institute Strategic Advances - HIV/AIDS Ongoing 21,700,000 ER 3.1
ER 3.2
CSC Custody Institutional Health Services Ongoing 4,187,261 ER 4.1
ER 4.2
Total for all federal organizations Ongoing 70,505,687 N/A

Expected Results for 2015–16:

ER 1.1: Public health decisions and interventions are supported by laboratory reference service testing and the identification of new and existing HIV strains in Canada which directs attention to HIV outbreaks. Use of laboratory-generated knowledge is increased and laboratory research expertise and knowledge platforms are further consolidated, to develop a hub for global leadership in HIV research and viral diagnostics, outbreak response, and genetic linkages to risk of disease.

ER 1.2: Provinces and territories are engaged through the Public Health Network to increase pan-Canadian understanding of trends and factors associated with HIV and AIDS and related communicable diseases, through enhanced biological-behavioural surveillance, and using this surveillance to guide best practices in prevention and control efforts. Thirteen chapters of the Sexually Transmitted Infections Guidelines will be reviewed and five chapters of the HIV/AIDS Epi Updates publications will be revised.

ER 1.3: Public health and community capacity is enhanced to prevent and control HIV and AIDS and related communicable diseases, through integrated approaches to HIV and AIDS, related communicable diseases and health factors; renewed stakeholder engagement; targeted information products for key populations; training and knowledge exchange; and global engagement.

ER 2.1: Complete the development of a national framework that provides strategic direction to Health Canada's STBBI programming to reduce the incidence, prevalence and burden of STBBIs in First Nations on reserve in partnership with key stakeholders such as First Nations' leaders; federal organizations such as PHAC and CSC; provincial partners; experts; and health care workers.

ER 3.1: Scientific knowledge about the nature of HIV/AIDS and ways to address the disease is created and research capacity built across priority areas including co-morbid health conditions in people living with HIV and the search for an HIV cure.

ER 3.2: Coordination of a strategic research agenda is fostered through the initiation of a new strategic plan for 2015–2020; the creation and maintenance of partnerships; and research programs focused on key populations and interventions to enhance the prevention of HIV and other STBBI.

ER 4.1: Enhanced understanding of the prevalence of HIV/AIDS, other sexually transmitted and blood borne infections (STBBI) and other communicable diseases which facilitates prevention of new infections is achieved through comprehensive screening and assessment of offenders in federal penitentiaries.

ER 4.2: Offenders have increased knowledge and awareness of the nature of HIV/AIDS, other STBBIs and other communicable diseases and ways to address these diseases and associated chronic conditions as a result of educational activities and information materials which are informed by health surveillance. Particular emphasis will be placed on reducing stigma which may impede offender access to prevention, diagnosis, treatment, care and support.

Canadian HIV Vaccine Initiative (CHVI)

General Information

Name of horizontal initiative: Canadian HIV Vaccine Initiative (CHVI)

Name of lead department(s): Public Health Agency of Canada (Agency)

Federal partner organization(s): Health Canada (HC), Industry Canada (IC), Foreign Affairs, Trade and Development Canada (DFATD), and Canadian Institutes of Health Research (CIHR)

Non-federal and non-governmental partner(s): Non-governmental stakeholders, including research institutions and not-for-profit community organizations

Start date of the horizontal initiative: February 20, 2007

End date of the horizontal initiative: March 31, 2017

Total federal funding allocated (start to end date): 111,000,000

Funding contributed by non-federal and non-governmental partners: N/A

Description of the horizontal initiative:

Objective(s):

  • Advance the basic science of HIV vaccine discovery and social research in Canada and low- and middle-income countries (LMICs);
  • Support the translation of basic science discoveries into clinical research with a focus on accelerating clinical trials in humans;
  • Address the enabling conditions to facilitate regulatory approval and community preparedness;
  • Improve the efficacy and effectiveness of HIV Prevention of Mother-to-Child services in LMICs by determining innovative strategies and programmatic solutions related to enhancing the accessibility, quality, and uptake; and
  • Enable horizontal collaboration within the CHVI and with domestic and international stakeholders.

Why this HI is Necessary:

  • The CHVI is a key element in the GoC's commitment to a comprehensive, long-term approach to addressing HIV/AIDs domestically and internationally.

Intervention Method(s):

  • The CHVI is a collaborative undertaking between the GoC and the Bill & Melinda Gates Foundation (BMGF) to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration was formalized by a Memorandum of Understanding signed by both parties in August 2006 and renewed in July 2010.

Shared outcome(s):

Immediate (1–3 years) Outcomes:

  • Increased and improved collaboration and networking among researchers working in HIV vaccine discovery and social research in Canada and in LMICs;
  • Greater capacity for vaccines research in Canada;
  • Enhanced knowledge base; and
  • Increased readiness and capacity in Canada and LMICs.

Intermediate Outcomes:

  • Strengthened contribution to global efforts to accelerate the development of safe effective, affordable, and globally accessible HIV vaccines;
  • An increase in the number of women receiving a complete course of anti-retroviral prophylaxis to reduce the risk of mother-to-child transmission of HIV; and
  • A strong and vibrant network (the CHVI Research and Development Alliance) of HIV vaccine researchers and other vaccine researchers, both in Canada and internationally is supported.

Long-term Outcome:

  • The CHVI contributes to the global efforts to reduce the spread of HIV/AIDS particularly in LMICs.

Governance structures:

  • The Minister of Health, in consultation with the Minister of Industry and the Minister of International Development and La Francophonie, is the lead for the CHVI;
  • An Advisory Board was established to oversee the implementation of the Memorandum of Understanding between the GoC and the BMGF, and also other duties such as making recommendations to responsible Ministers regarding projects to be funded; and
  • The CHVI Secretariat, housed in the Agency, will continue to provide a coordinating role to the GoC and the BMGF.
    • Continue initiatives such as improving domestic and international research projects, as well as continuing to support the Alliance Coordinating Office;
    • Undertake activities that will lead to a determination of the appropriate direction and next steps on the future the CHVI;
    • Host the 2015 Health Products and Food Branch International Regulatory Forum;
    • Support the CHVI Regulatory Capacity Building Mentorship Program, in cooperation with the World Health Organization (WHO) and the Pan-American Health Organization (PAHO), to contribute to the World Health Assembly's resolutions 67.20 and 67.22 on regulatory systems, and continuing delivery of the Canadian HIV Technology Development Program;
    • Explore monoclonal antibody capacity in Canada; continuing to support implementation research to eliminate mother-to-child transmission of HIV in sub-Saharan Africa;
    • Support knowledge creation and strengthened HIV vaccine research capacity through ongoing support to CHVI investigators and teams;
    • Enhance linkages among researchers, stakeholders and funders through participation in collaborative activities and sharing of research outcomes; and
    • Support co-ordinated activities that link and communicate with HIV vaccine researchers, and partners and stakeholders.

Planning highlights:Footnote 9

Results to be achieved by non-federal and non-governmental partners: N/A

Contact information:
Jacqueline Arthur,
Manager, Strategic Issues, Centre for Communicable Diseases and Infection Control,
100 Eglantine Driveway
Ottawa, Ontario K1A 0K9
613-946-0822
jacqueline.arthur@phac-aspc.gc.ca

Planning Information
Federal organizations Link to departmental Program Alignment Architectures Contributing programs and activities Total allocation (from start to end date) 2015–16 Planned spending 2015–16 Expected results
The Agency Health Promotion and Disease Prevention Healthy Communities 18,000,000 1,231,978 ER 1.1
ER 1.2
ER 1.3
ER 1.4
HC Internal Services Governance and Management Support Services 1,000,000 0 ER 2.1
Health Products Regulatory Capacity Building Program for HIV Vaccines 4,000,000 1,042,000 ER 2.1
ER 2.2
IC Commercialization and Research and Development Capacity in Targeted Canadian Industries Industrial Research Assistance Program's Canadian HIV Technology Development Component 13,000,000 2,500,000 ER 3.1
DFATD Global Engagement and Strategic Policy International Development Assistance Program 60,000,000 2,400,000 ER 4.1
ER 4.2
CIHR Health and Health Services Advances Institute Strategic Advances - HIV/AIDS 15,000,000 1,660,000 ER 5.1
ER 5.2
Total for all federal organizations 111,000,000 8,833,978 N/A

Expected Results for 2015–16:

ER 1.1: Continue to support domestic and international efforts related to the research and development of an HIV vaccine.

ER 1.2: Support the continued work of the Alliance Coordinating Office to establish a strong and vibrant network of HIV vaccine researchers and other vaccine researchers both in Canada and internationally.

ER 1.3: Enable effective communications, strategic planning, coordination, reporting and evaluation within the GoC.

ER 1.4: Lead interdepartmental activities related to determining the future of the CHVI.

ER 2.1: Increased regulatory convergence and exchange of domestic and international best practices, policies, and protocols related to the regulation of vaccines, with a focus on HIV/AIDS vaccines.

ER 2.2: Increased regulatory readiness and strengthened capacity of regulatory authorities in LMICs in the area of vaccine products and clinical trials through training and the establishment of a mentorship program.

ER 3.1: New and innovative technologies for the prevention, treatment, and diagnosis of HIV in pre-commercial development are advanced in small-and medium-sized enterprises operating in Canada.

ER 4.1: In collaboration with CIHR, increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs.

ER 4.2: Enhanced knowledge of communities, health care workers, and Ministry of Health staff in LMICs on the prevention of mother-to-child transmission of HIV and maternal, newborn, and child health issues.

ER 5.1: Continued knowledge creation and strengthened HIV vaccine research capacity.

ER 5.2: Enhanced linkages amongst researchers, stakeholders, and funders.

Footnote 7
7Updates to the FI logic model and performance measurement strategy are currently under development and will be implemented starting in 2015–16. First and second level outcomes may be adjusted to reflect the evolution of this mature horizontal initiative.
Footnote 8
8The FI logic model and performance measurement strategy are currently under development and will be available and implemented in 2015–16.
Footnote 9
9The CHVI logic model and performance measurement strategy are currently under development and will be available and implemented in 2015–16.

Page details

Date modified: